TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31564057
Drug: Dupilumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab with topical corticosteroids
Study: 22039269
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (CS injection)
Study: 20929584
Drug: Individual Dietary
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual Dietary and Activity Planning (IDAP) - goal-setting with a daily reduction of 600 kcal
Study: 10771456
Drug: Ziprasidone 40
Normalized name: ziprasidone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 40 mg day(‐1) on days 9‐11 followed by 80 mg day(‐1) on days 12‐15
Study: 9387729
Drug: Zhenkeling oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhenkeling oral liquor (ZKL group)
Study: 9387729
Drug: Pectoral syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectoral syrup (control group)
Study: 1343611
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral low-dose (7.5 mg) methotrexate (MTX) for 2 years
Study: 1343611
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral low-dose (7.5 mg) methotrexate (MTX)
Study: 2864738
Drug: Gastric inhibitory
Normalized name: Gastric inhibitory peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric inhibitory polypeptide (GIP) in pharmacological doses
Study: 2864738
Drug: Cholecystokinin (CCK)
Normalized name: cholecystokinin
DrugBank: Cholecystokinin (DB08862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecystokinin (CCK) in pharmacological doses
Study: 2864738
Drug: Somatostatin in
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin in pharmacological doses
Study: 30880951
Drug: batefenterol 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: batefenterol 37.5 µg
Study: 30880951
Drug: batefenterol 75
Normalized name: Batefenterol
DrugBank: Batefenterol (DB12526)
Approvals — FDA: no, EMA: no, PMDA: no
Description: batefenterol 75 µg
Study: 30880951
Drug: batefenterol 150
Normalized name: Batefenterol
DrugBank: Batefenterol (DB12526)
Approvals — FDA: no, EMA: no, PMDA: no
Description: batefenterol 150 µg
Study: 30880951
Drug: batefenterol 300
Normalized name: Batefenterol
DrugBank: Batefenterol (DB12526)
Approvals — FDA: no, EMA: no, PMDA: no
Description: batefenterol 300 µg
Study: 30880951
Drug: batefenterol 600
Normalized name: Batefenterol
DrugBank: Batefenterol (DB12526)
Approvals — FDA: no, EMA: no, PMDA: no
Description: batefenterol 600 µg
Study: 30880951
Drug: umeclidinium/vilanterol (UMEC/VI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: umeclidinium/vilanterol (UMEC/VI) 62.5/25 µg
Study: 24344049
Drug: Mangifera indica
Normalized name: MANGIFERA INDICA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mangifera indica extract (Vimang tablets, 900 mg/day) combined with methotrexate (MTX, 12.5 mg/week)
Study: 24344049
Drug: Methotrexate (MTX,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (MTX, 12.5 mg/week) without Vimang extract
Study: 17474183
Drug: Cholinergic agents
Normalized name: ANTICHOLINERGIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinergic agents
Study: 17474183
Drug: NMDA agonists
Normalized name: NMDA
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NMDA agonists
Study: 17474183
Drug: Cognitive interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive interventions including rehabilitation pharmacotherapy
Study: 17474183
Drug: Drugs strategically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs strategically coupled to cognitive-behavioral treatments
Study: 16136052
Drug: Chemotherapy started
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy started within 3 months of surgery (CMF, CMF i.v., cyclofosfamide, epirubicin, and 5‐fluorouracil)
Study: 16136052
Drug: Chemotherapy started
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy started after 3 months of surgery (delayed start)
Study: 12182269
Drug: Patients' expectancies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients' expectancies of treatment effectiveness
Study: 2140838
Drug: Ketanserin 40
Normalized name: ketanserin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 40 mg/day (KE40)
Study: 2140838
Drug: Ketanserin 80
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 80 mg/day (KE80)
Study: 507944
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment and oral administration of BCG
Study: 28397242
Drug: Ibrutinib with
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib with concomitant anticoagulant or antiplatelet agents (175 patients)
Study: 28397242
Drug: Ibrutinib alone
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib alone (without anticoagulants or antiplatelets)
Study: 26362110
Drug: Oral collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral collagen peptide supplementation
Study: 15307407
Drug: Community-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based intervention to improve skills of village drug kit managers
Study: 10392251
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue treatment
Study: 6441014
Drug: Standard polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard polyethylene catheter plus heparin
Study: 6441014
Drug: Polyurethane catheter
Normalized name: polyurethane-62
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyurethane catheter without heparin
Study: 30879111
Drug: Received cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Received cumulative dose over time
Study: 30270762
Drug: Intensive aphasia
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive aphasia therapy
Study: 24820104
Drug: Complete immunization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete immunization schedule (7 vaccines and 15 doses)
Study: 21987582
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (prednisolone sodium phosphate, 1.0%)
Study: 17567657
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin for 7 days (n = 126)
Study: 15718308
Drug: C‐HART (70.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: C‐HART (70.6 Gy) with concurrent FU (600 mg/m(2), 120 hours continuous infusion) and MMC (10 mg/m(2))
Study: 2676220
Drug: Etidocaine 1%
Normalized name: etidocaine 1% preservative-free injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidocaine 1% at 2 mg.kg‐1
Study: 2676220
Drug: Bupivacaine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 1.5 mg.kg‐1
Study: 22078153
Drug: LDA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDA plus naproxen/esomeprazole magnesium (500 mg naproxen and 20 mg esomeprazole magnesium, twice daily on days 6-10)
Study: 22078153
Drug: LDA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDA plus placebo (81 mg LDA once daily on days 1-5 and placebo twice daily on days 6-10)
Study: 11289473
Drug: Metformin (2,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2,550 mg/day for 14 days)
Study: 11289473
Drug: Metformin (0.1-0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (0.1-0.5 microg/ml) in pooled human plasma
Study: 1080961
Drug: Intravenous high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous high dose methotrexate and leucovorin rescue
Study: 28557555
Drug: β1 blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β1 blocker nebivolol
Study: 23140546
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment in current smokers (n=129)
Study: 19543892
Drug: Cervical TFESI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical TFESI using triamcinolone (particulate steroid)
Study: 19543892
Drug: Cervical TFESI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical TFESI using dexamethasone (non-particulate steroid)
Study: 22392497
Drug: Peach shake
Normalized name: AVOBENZONE 2.7 g in 100 g / OCTINOXATE 6 g in 100 g TOPICAL LIPSTICK [GOLDEN ROSE GLOW KISS TINTED LIP BALM PEACH SHAKE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peach shake meal (PSM) (SA: 0.06 ± 0.001 mg/100 g)
Study: 15774433
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT), 12-14 sessions
Study: 9469276
Drug: Intraumbilical oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraumbilical oxytocin (20 IU in 20 mL of saline)
Study: 9469276
Drug: Intraumbilical saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraumbilical saline (20 mL)
Study: 8535640
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sulphasalazine (SASP) and methotrexate (MTX)
Study: 2404049
Drug: Low-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat diet intervention (15% of energy intake) with bi-weekly individual counseling sessions
Study: 11483335
Drug: Androgen ablation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen ablation (goserelin 3.6 mg every 4 weeks and flutamide 250 mg t.i.d. for 2 months before and during radiation therapy)
Study: 24461613
Drug: Indacaterol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol (150 μg)
Study: 21225011
Drug: Preseasonal prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preseasonal prophylactic treatment with antihistamines (2-4 weeks before pollen season)
Study: 7637479
Drug: Injected polio
Normalized name: poliovirus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected polio vaccine (IPV)
Study: 2491766
Drug: Corticosteroids plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids plus thyrotropin-releasing hormone (TRH)
Study: 870513
Drug: Ovine prolactin
Normalized name: prolactin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovine prolactin (25 mg)
Study: 22159928
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 ml normal saline)
Study: 870513
Drug: Ovine prolactin
Normalized name: prolactin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovine prolactin (100 mg)
Study: 26666324
Drug: Novel oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel oral anticoagulants (NOACs) including dabigatran etexilate, rivaroxaban, apixaban, and edoxaban.
Study: 26666324
Drug: Classic anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classic anticoagulants like heparin, low‐molecular‐weight heparins (LMWHs), fondaparinux, and vitamin K antagonists.
Study: 21199290
Drug: 200 mcg
Normalized name: CrM 200 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg sublingual misoprostol
Study: 21199290
Drug: 600 mcg
Normalized name: Biotin 600 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mcg sublingual misoprostol
Study: 24365208
Drug: Intramuscular oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular oxytocin (10 IU)
Study: 16409193
Drug: Grass allergen
Normalized name: orchardgrass allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass allergen tablet (SQ-T) at various doses (25,000 to 1,000,000 standardized quality tablet)
Study: 16409193
Drug: Grass allergen
Normalized name: orchardgrass allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass allergen tablet (SQ-T)
Study: 12744860
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine (5 doses)
Study: 12744860
Drug: Whole‐cell pertussis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole‐cell pertussis vaccine (5 doses)
Study: 10561296
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m(2) every 3 weeks
Study: 10561296
Drug: Doxorubicin 75
Normalized name: DOXOrubicin 75 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 75 mg/m(2) every 3 weeks
Study: 8739678
Drug: latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: latanoprost 0.005% once daily (morning dose)
Study: 8739678
Drug: latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: latanoprost 0.005% once daily (evening dose)
Study: 3529971
Drug: timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: timolol 0.5% twice daily
Study: 1820640
Drug: 7-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7-day regimen of oral artesunate at 600 mg
Study: 1820640
Drug: 5-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-day regimen of oral artesunate at 600 mg
Study: 6755786
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 325 mg and placebo
Study: 6755786
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) and dipyridamole (DIP) 325 mg and 75 mg
Study: 6755786
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) and dipyridamole (DIP)
Study: 31361815
Drug: Supportive text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive text messages (twice-daily) over 6 months
Study: 31361815
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual for 6 months
Study: 23102885
Drug: Thrombolysis group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolysis group (TG) - low-dose tissue plasminogen activator plus anticoagulation (n=61)
Study: 22578727
Drug: Adjuvant androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant androgen deprivation therapy
Study: 2827456
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran (30 g added to formula meal)
Study: 28809383
Drug: Full-dose α-galactosidase
Normalized name: ALPHA-GALACTOSIDASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose α-galactosidase (300 GALU)
Study: 28809383
Drug: Half-dose α-galactosidase
Normalized name: ALPHA-GALACTOSIDASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose α-galactosidase (150 GALU)
Study: 28137316
Drug: time‐intensive cognitive‐behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: time‐intensive cognitive‐behaviour therapy (iCBT)
Study: 25639732
Drug: Gestalt and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestalt and lucid dreaming group therapy (LDG)
Study: 25639732
Drug: Gestalt therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestalt therapy group (GTG)
Study: 18374458
Drug: Seal oil
Normalized name: seal oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seal oil (10 mL, 3 times a day for 14 days)
Study: 18374458
Drug: Cod liver
Normalized name: Cod Liver Oil
DrugBank: Cod liver oil (DB11321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod liver oil (10 mL, 3 times a day for 14 days)
Study: 16685542
Drug: Topical furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical furosemide (6.6 mmol/l solution)
Study: 29210507
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid syrup (IFAS) administered twice weekly for 1 month
Study: 26875894
Drug: Argon plasma
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argon plasma coagulation combined high frequency electric knife therapy
Study: 21872537
Drug: Personalized interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Personalized interventions developed using the Treatment Routes for Exploring Agitation decision tree protocol
Study: 15965635
Drug: Spa therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa therapy (n = 16) for 2 weeks in addition to medical treatment
Study: 15965635
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 14) continued medical treatment and/or daily exercises
Study: 15965635
Drug: Spa therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa therapy (n = 16)
Study: 11896092
Drug: 4 x
Normalized name: Mepilex AG 4 x 4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x DOC (100 mg/m(2))
Study: 10207925
Drug: Acetazolamide (ACZ)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (ACZ) and furosemide (FUR) treatment
Study: 29110972
Drug: Dulaglutide 1.5
Normalized name: dulaglutide 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 1.5 mg added to insulin glargine
Study: 29110972
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to insulin glargine
Study: 22020607
Drug: Epidural administration
Normalized name: epidural administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural administration of 10 mg of etanercept and 2.0 mL of lidocaine
Study: 22020607
Drug: Epidural administration
Normalized name: epidural administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural administration of 3.3 mg of dexamethasone and 2.0 mL of lidocaine
Study: 17761319
Drug: Active extracorporeal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active extracorporeal shockwave therapy (0.25 mJ/mm(2))
Study: 17761319
Drug: Sham shockwave
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham shockwave therapy
Study: 15066896
Drug: QI-meds and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: QI-meds and QI-therapy
Study: 8664455
Drug: Insulin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (1.5 U/kg/h)
Study: 1972963
Drug: Sunflowerseed oil
Normalized name: Sunflowerseed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflowerseed oil (60 ml/day)
Study: 1972963
Drug: Linseed oil
Normalized name: linseed oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linseed oil (60 ml/day)
Study: 1972963
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (60 ml/day)
Study: 340006
Drug: Indoprofen 800
Normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indoprofen 800 mg/day
Study: 369924
Drug: Indomethacin 80
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin 80 mg/day
Study: 27003895
Drug: Single subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous injection of FE 999049 at doses of 37.5, 75, 150, 225, or 450 IU
Study: 19278583
Drug: Ulinastatin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin and thymosin alpha1, 200 kU IV twice a day for 4 days, then 100 kU for 6 days; thymosin alpha1, 1.6 mg subcutaneous twice a day for 4 days, then 1.6 mg per day for 6 days.
Study: 19278583
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received conventional treatment according to Surviving Sepsis Campaign (SSC) 2004.
Study: 7935897
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (received a list with actual medication and recommendations by the pharmacist)
Study: 7935897
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (control group, sent prescriptions as before)
Study: 7935897
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (received a list with medication used by their patients)
Study: 29246950
Drug: Exenatide ER
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide ER 2.0 mg
Study: 27481188
Drug: Transarterial chemoembolization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transarterial chemoembolization (TACE) with bicarbonate local infusion
Study: 27481188
Drug: Transarterial chemoembolization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transarterial chemoembolization (TACE) without bicarbonate local infusion
Study: 24708031
Drug: Tiotropium plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium plus Indacaterol (combined therapy)
Study: 23000116
Drug: Intervention (annual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (annual prostate-specific antigen for 6 years and digital rectal exam for 4 years)
Study: 20518086
Drug: Viusid (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viusid (3 sachets daily)
Study: 15739653
Drug: UlcerCare leg
Normalized name: Crab leg
DrugBank: Crab leg (DB11011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UlcerCare leg wrap (treatment)
Study: 10614952
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin 200 mg
Study: 8157551
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin 400 mg
Study: 8157551
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin 500 mg
Study: 3529803
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate (Healon) + 500 mg acetazolamide at the end of surgery (Group II)